Skip to main content
. 2022 Nov;10(22):1228. doi: 10.21037/atm-22-5352

Figure 1.

Figure 1

Median IC-PFS times of pyrotinib + radiotherapy vs. pyrotinib-based therapy in the 2 groups. IC-PFS, intracranial progression-free survival; HR, hazard ratio; CI, confidence interval.